Global Health Challenge for Industry R&D and Access to Care
The Global Health Challenge for Industry R&D and Access to Care
Overview of Global Health and Pharmaceutical Industry
Dr. Hannah Kettler, an economist and Senior Program Officer at the Bill & Melinda Gates Foundation, discusses the intersection of R&D, health delivery goals, and the pharmaceutical industry.
The missions of both the global health and pharmaceutical sectors converge, focusing on securing a healthy and productive life for individuals.
Evolution of the Global Health Sector
Progression: Over the last decade, the global health community has expanded and refined its strategies, particularly those of the Gates Foundation.
Shift from macro-structures (e.g., GAVI Alliance, Global Fund) to targeted resource allocation based on effectiveness.
Initial focus was on merely increasing the quantity of funding and products now shifting towards quality and effectiveness of health interventions.
Definition and Focus of Global Health
Global Health: Refers to health issues that significantly impact developing countries yet suffer from inadequate attention and funding.
Health issues include:
Enteric and diarrheal diseases
HIV/AIDS
Malaria
Tuberculosis
Neglected tropical diseases
Maternal, neonatal, and child health
Engagement of Pharmaceutical Industry
The pharmaceutical industry's involvement has broadened and diversified, leading to improved partnerships and effectiveness in addressing global health needs.
Notable progress includes unprecedented improvements against curable diseases and poverty, highlighted by significant initiatives such as childhood immunization efforts.
Example: As part of partnerships (e.g., GAVI), 288 million children have been immunized since 2000, saving over 5.5 million lives.
Immunization Efforts and Impact
GAVI's Role: GAVI initially aimed to boost routine immunization rates and introduced vaccines that had become affordable and accessible to developing countries post-1980s.
Expanded access to new vaccines like rotavirus and pneumonia.
Companies now tend to introduce products simultaneously in developed and developing countries, enhancing the potential to decrease disease burdens in the latter.
Stability in Vaccine Supply
GAVI has played a pivotal role in stabilizing the vaccine supply chain, which had been problematic in the 1990s.
The number of companies engaged in vaccine development has increased significantly due to GAVI’s influence, with multiple suppliers for routine vaccines now available, especially from emerging markets (e.g., China, Brazil, India).
Addressing Access to Medicines
The pharmaceutical industry faces significant challenges regarding access to medicines, particularly in developing areas where investment is minimal due to low revenue projections compared to other market areas.
Increased focus is necessary for new tools treating priority diseases affecting impoverished populations.
Regulatory systems are adapting to streamline processes, e.g., “adaptive licensing” allows for faster combination drug testing.
Case Study: Meningitis A Vaccine
An example of successful partnership work leading to innovation includes the development of MenAfriVac, an affordable meningitis vaccine ideal for sub-Saharan Africa.
Key partners: Serum Institute of India, WHO, PATH.
Challenges and Collaborative Strategies
The Gates Foundation takes a collaborative approach to meet pressing health needs, with specific goals for diseases such as polio, HIV/AIDS, malaria, pneumonia, and neglected tropical diseases.
Medicines for Malaria Venture (MMV): An example of a product development partnership aimed at addressing malaria treatments effectively.
Push and Pull Incentives in R&D
The Foundation uses its balance sheet to incentivize R&D through targeted equity investments in biotechnology, alongside traditional grant funding.
Volume guarantees: These are offered to ensure affordable pricing for developing countries, leading to lower costs while securing vaccine supply, as exemplified by the OPV market.
Shifts in Partnership Dynamics
Growing trends show pharmaceutical companies’ willingness to engage more proactively with global health issues, highlighted by the January 2012 London Declaration aimed at combating neglected tropical diseases.
Innovative financing and partnerships are emerging in family planning, with companies offering significant price reductions for essential reproductive health tools.
Funding Landscape and Future Directions
Despite ongoing funding challenges, active partnerships and innovative collaboration are crucial.
Triangular partnerships are being explored to increase investment, incorporating emerging economies alongside traditional donors for R&D initiatives.
Countries like Brazil, China, and India are being targeted for potential R&D collaboration, given their investment in biotechnology.
Monitoring and Accountability in Health Programs
Responsibility for monitoring the safety and effectiveness of health products on the market can vary:
Technically, companies hold responsibility, but many manufacturers may lack resources for systematic post-approval surveillance.
Partnerships (including the Gates Foundation) are expanding efforts to collect data on product performance, especially for diseases like malaria.
Conclusion
The Global Health community and the Gates Foundation foster a dedication to improving health outcomes through refined partnerships with the pharmaceutical industry. Acknowledgment of mutual benefits marks a significant shift in global health dynamics today.
Drug development, particularly in the context of global health, faces several significant challenges as outlined in the text: . Economic Disincentives: Investment in developing areas is often minimal because revenue projections are low compared to other market segments, leading to inadequate attention for diseases affecting impoverished populations. . High R&D Risks and Costs: Developing new drugs is expensive and carries high financial risk; organizations like the Gates Foundation use 'Push and Pull' incentives and volume guarantees to mitigate these risks for companies. . Regulatory Hurdles: Traditional regulatory processes can be slow; the notes mention 'adaptive licensing' as a necessary evolution to streamline the testing of drug combinations. . Post-Approval Surveillance: Many manufacturers lack the resources for systematic monitoring of drug safety and effectiveness once products reach the market, shifting the data collection burden to partnerships. . Supply Chain Stability: Maintaining a stable and affordable supply of vaccines requires complex coordination across various global suppliers and emerging markets like China, Brazil, and India to avoid the supply issues experienced in the s.